Search

Displaying results 2881 - 2890 of 7452 in total
  1. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  2. Drug

    Dienestrol

    go.drugbank.com/drugs/DB00890
    ApprovedWithdrawn

    Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva.

  3. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopaus...

    Categories: Antidepressive Agents Indicated for Depression
  4. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic

  5. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.

  6. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. … Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

  8. Drug

    Norflurane

    go.drugbank.com/drugs/DB13116
    ApprovedInvestigationalWithdrawn

    Norflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).

  9. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

  10. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.